Laboratory of Pharmacokinetic/Pharmacogenomic, Regina Elena National Cancer Institute, Rome, Italy.
J Exp Clin Cancer Res. 2012 Jan 24;31(1):7. doi: 10.1186/1756-9966-31-7.
The aim of this study was to evaluate the potential association between single nucleotide polymorphisms related response to radiotherapy injury, such as genes related to DNA repair or enzymes involved in anti-oxidative activities. The paper aims to identify marker genes able to predict an increased risk of late toxicity studying our group of patients who underwent a Single Shot 3D-CRT PBI (SSPBI) after BCS (breast conserving surgery).
A total of 57 breast cancer patients who underwent SSPBI were genotyped for SNPs (single nucleotide polymorphisms) in XRCC1, XRCC3, GST and RAD51 by Pyrosequencing technology. Univariate analysis (ORs and 95% CI) was performed to correlate SNPs with the risk of developing ≥ G2 fibrosis or fat necrosis.
A higher significant risk of developing ≥ G2 fibrosis or fat necrosis in patients with: polymorphic variant GSTP1 (Ile105Val) (OR = 2.9; 95%CI, 0.88-10.14, p = 0.047).
The presence of some SNPs involved in DNA repair or response to oxidative stress seem to be able to predict late toxicity.
ClinicalTrials.gov: NCT01316328.
本研究旨在评估与放射治疗损伤反应相关的单核苷酸多态性（如与 DNA 修复相关的基因或参与抗氧化活性的酶）的潜在关联。本文旨在通过研究我们组接受乳腺癌保乳手术后单次 3D-CRT PBI（SSPBI）治疗的患者，确定能够预测晚期毒性风险的标记基因。
对 57 名接受 SSPBI 治疗的乳腺癌患者进行 XRCC1、XRCC3、GST 和 RAD51 基因的单核苷酸多态性（SNP）基因分型，采用焦磷酸测序技术。采用单因素分析（OR 和 95%CI）将 SNP 与发生≥G2 纤维化或脂肪坏死的风险相关联。
GSTP1（Ile105Val）多态性（OR=2.9；95%CI，0.88-10.14，p=0.047）患者发生≥G2 纤维化或脂肪坏死的风险显著增加。
一些参与 DNA 修复或氧化应激反应的 SNP 似乎能够预测晚期毒性。
ClinicalTrials.gov：NCT01316328。
